DYAX: Dyax Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DYAX: Dyax Corp.

DYAX 38.41

0.0%

Jan 25 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	1/26/2006 12:16:57 PM
	Read Replies (1) of 197

medicalnewstoday.com Heart Surgery Drug Raises Kidney Failure Risk Category: Cardiovascular/Cardiology News Article Date: 26 Jan 2006 - 15:00pm (UK) Trasylol (aprotinin) is a drug surgeons use to control bleeding during heart surgery. New research has found that aprotinin also doubles the risk of kidney failures. The researchers who took part in this new study say the drug should be dropped. Aprotinin has other risks: Patients have a 48% higher risk of a heart attack, heart failure risk is 109% higher and stroke a whopping 181%. Aprotinin is produced and owned by Bayer Corp. Every year, over 11,000 patients need kidney dialysis as a result of having been given this drug during heart surgery. You can read about this study in The New England Journal of Medicine. Other cheaper and safer drugs are available, say the scientists. They said doctors should inform the patient about the drug's risks if they still wish to use it. Aprotinin has been on the market for over 12 years. In this study over four thousand patients were looked at - they had all had heart operations. Areas covered included North America, Europe Colombia, Israel and Thailand. The FDA says the drug is under review. Written by: Christian Nordqvist Editor: Medical News Today

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next